{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:13:53Z","timestamp":1789150433300,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["seminoncol.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1053\/j.seminoncol.2016.11.012","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T13:40:39Z","timestamp":1479303639000},"page":"690-694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of multiple myeloma in resource-constrained settings"],"prefix":"10.1053","volume":"43","author":[{"given":"Lalit","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Kumar Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2016.11.012_bib1","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1056\/NEJMc1310911","article-title":"Treatment for high-risk smoldering myeloma","volume":"369","author":"Kristinsson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib2","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib5","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood-2015-10-662320","article-title":"Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib6","unstructured":"Smoldering multiple myeloma: when to observe and when to treat? J Clin Oncol http:\/\/meetinglibrary.asco.org\/content\/11500484-156. Accessed August 28, 2016."},{"key":"10.1053\/j.seminoncol.2016.11.012_bib7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib8","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1038\/bcj.2015.87","article-title":"Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy","volume":"5","author":"Siontis","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib9","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment With carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib10","unstructured":"Carfilzomib in treatment patients under 65 years with high risk smoldering multiple myeloma. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02415413. Accessed September 13, 2016."},{"key":"10.1053\/j.seminoncol.2016.11.012_bib11","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib12","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation","volume":"117","author":"Cavo","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib13","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib14","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib15","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2015.80","article-title":"Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma","volume":"29","author":"Mai","year":"2015","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib16","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib17","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/bmt.2008.343","article-title":"High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country","volume":"43","author":"Kumar","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clml.2013.09.001","article-title":"High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells","volume":"14","author":"Kayal","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib20","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-0609.2010.01466.x","article-title":"High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents","volume":"85","author":"Terpos","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib22","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1016\/S1470-2045(13)70404-2","article-title":"Management of multiple myeloma in Asia: resource-stratified guidelines","volume":"14","author":"Tan","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clml.2012.08.007","article-title":"Autologous stem cell transplantation for multiple myeloma: identification of prognostic factors","volume":"13","author":"Kumar","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/cam4.257","article-title":"Complete response after autologous stem cell transplant in multiple myeloma","volume":"3","author":"Kumar","year":"2014","journal-title":"Cancer Med"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib25","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.V126.23.25.25","volume":"126","author":"Durie","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib27","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.clml.2015.07.189","article-title":"Induction regimens for autologous transplant (AHCT) eligible myeloma (MM) patients (pts)\u2014doublets or triplets and which triplet?","volume":"15","author":"Hari","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib28","doi-asserted-by":"crossref","DOI":"10.11622\/smedj.2016150","article-title":"The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma","author":"de Mel","year":"2016","journal-title":"Singapore Med J"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib29","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1038\/bcj.2015.79","article-title":"Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma","volume":"5","author":"Ozaki","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib30","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.3109\/10428194.2015.1135434","article-title":"Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China","volume":"57","author":"Lu","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMp1304400","article-title":"Engineered in India\u2014patent law 2.0","volume":"369","author":"Kapczynski","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib32","unstructured":"Myeloma in India: CureTalk in conversation with Dr. Lalit Kumar, Professor of Medical Oncology, All India Institute of Medical Sciences (AIIMS), Delhi, India. CureTalks Blog. http:\/\/trialx.com\/curetalk\/2013\/03\/13\/myeloma-in-india-curetalk-in-conversation-with-dr-lalit-kumar-professor-of-medical-oncology-all-india-institute-of-medical-sciences-aiims-delhi-india\/. Accessed September 6, 2016."},{"key":"10.1053\/j.seminoncol.2016.11.012_bib33","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/j.clml.2015.07.349","article-title":"Low dose dexamethasone plus lenalidomide (Len-dexa) versus thalidomide (Thal-dexa) as induction therapy for newly diagnosed multiple myeloma: a phase III, randomized study","volume":"15","author":"Kumar","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib34","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","article-title":"Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival","volume":"26","author":"Lahuerta","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib35","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib36","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib37","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.bbmt.2012.11.065","article-title":"Cost effectiveness decision tree analysis of early versus late autologous stem cell transplantation (ASCT) in multiple myeloma (MM) in the United States (US)","volume":"19","author":"Hashmi","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood.V126.23.391.391","article-title":"Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone Du Myelome (IFM\/DFCI 2009 Trial)","volume":"126","author":"Attal","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2014.04.011","article-title":"Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee","volume":"14","author":"Raje","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib40","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clml.2015.07.171","article-title":"A meta-analysis investigating the impact of minimal residual disease (MRD) status on survival outcomes in patients with multiple myeloma (MM) who achieve complete response (CR)","volume":"15","author":"Munshi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2016.1228930","article-title":"Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma","author":"Gupta","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib42","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib43","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib44","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","article-title":"IMWG consensus on maintenance therapy in multiple myeloma","volume":"119","author":"Ludwig","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib45","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/bmt.2015.83","article-title":"Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib46","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib47","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa de Magalhaes","year":"2013","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib49","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.11.012_bib50","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377541630121X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009377541630121X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T16:35:18Z","timestamp":1718901318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009377541630121X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S009377541630121X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.11.012","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of multiple myeloma in resource-constrained settings","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}